about
Effects of Ang II receptor blocker irbesartan on adipose tissue function in mice with metabolic disordersEffects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders.Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II-infused miceEplerenone-Resistant Salt-Sensitive Hypertension in Nedd4-2 C2 KO MiceDeletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertensionBofu-tsu-shosan, an oriental herbal medicine, exerts a combinatorial favorable metabolic modulation including antihypertensive effect on a mouse model of human metabolic disorders with visceral obesity.Renal tubule angiotensin II type 1 receptor-associated protein promotes natriuresis and inhibits salt-sensitive blood pressure elevationAngiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology.Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemiaThe angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney diseaseEnhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertensionUpstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein.Potential beneficial impact of angiotensin receptor blockers on arterial stiffness in hypertension.Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesityATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice.The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap.Involvement of Runx3 in the basal transcriptional activation of the mouse angiotensin II type 1 receptor-associated protein gene.An Isoform of Nedd4-2 Plays a Pivotal Role in Electrophysiological Cardiac Abnormalities.Adipocyte-Specific Enhancement of Angiotensin II Type 1 Receptor-Associated Protein Ameliorates Diet-Induced Visceral Obesity and Insulin Resistance.Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.Angiotensin II Type 1 Receptor-Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin.Rituximab treatment for adult purpura nephritis with nephrotic syndrome.Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension.Modelling diabetic nephropathy in mice.Possible impact of electronegative LDL on atherosclerosis in type 2 diabetes.Within-visit blood pressure variability and cardiovascular risk factors in hypertensive patients with non-dialysis chronic kidney disease.Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile.Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue.Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases.An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model.Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.Possible therapeutic impact of the iron chelation on renal fibrosis.Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.Fetal programming by high-sucrose diet during pregnancy affects the vascular angiotensin II receptor-PKC-L-type Ca(2+) channels (Cav1.2) axis to enhance pressor responses.Early Enhanced Leucine-Rich -2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model MiceEffects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused miceEffects of ATRAP in Renal Proximal Tubules on Angiotensin-Dependent HypertensionCombination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY)
P50
Q33611545-F56394A2-C05C-4C32-8CA2-B4C01A2C0584Q33767895-F18935F7-C7F9-45F9-98ED-5D1F17DD5E59Q33800266-4D6D3CE6-8ADD-4DD2-959E-E74747E2C0F9Q33838875-29D032A3-D853-47C1-B093-4E1719740F70Q34111828-D54289E3-0433-4D94-80D6-683167753321Q35018311-427186C7-74DE-4155-BC7D-5B7DA0DB423CQ35354119-D0D0AEB6-119E-472F-9109-2067801B2949Q35752131-5C7B0F13-D227-465C-977C-F5654D19B818Q36357758-8105555F-AE65-45F2-BDEE-588C4D70A823Q36675029-1D9B0CA4-1F69-4BFD-94E4-04D9579639A5Q36853518-C61E9150-B03C-45C0-8FD2-1D42EA038103Q36967420-59ACD43D-9053-4C75-A541-E31B08ABA056Q37121439-3FAB8977-EABF-462F-8E3F-750956EC5EC5Q37139028-38FEF50F-619C-4753-8493-6981D62CECA1Q37139236-7BA05E08-C442-42C3-A4B9-A82C5B04A60CQ37310527-DF8168CA-CD1D-48EF-9CB0-676ED7820F4DQ37729369-C8F92F3E-28F3-4157-ACA3-57229F285372Q38061953-3B4E7ECB-F7D5-45DC-950D-EED5E84DB328Q39540857-F5CA1F67-2F9C-4143-B77D-88EA1E15459EQ41033739-C7CD431C-4E36-4346-ABE1-D5C805CB0B0FQ41103828-2FDC0DDB-056D-4FCA-8E2C-2CC7EA3E703DQ41187803-6412DB37-6DE6-4D2E-A1E9-BCDC0697A088Q41628398-169218A9-CC3D-43FF-9AC8-D17CABED6A6FQ46578700-DC585527-E027-40CB-A703-376F1DD0BAADQ46975525-607651AE-CC4F-4EB6-9EF9-D2553408DAF6Q47735079-44D1E2F4-5CC2-4C48-94C5-7FD41AD3045BQ47887907-13A97FC2-15BC-4286-BBCF-E8BDCD2BAC72Q48246287-6EDB59CC-B6FC-4CF0-AE48-F7E4049BD756Q48499987-02622023-39EB-40DC-B57E-DBB08DFE54DBQ49345079-6230DFA6-FAC2-4819-9ED7-DB4722668839Q51019364-82AD5EF5-6111-4E0E-AD99-997F85339D59Q51194907-F70048BE-319A-4C00-9C1E-D97287C81F27Q51687884-400F7F36-2D64-453F-9C16-D4BF73F822B2Q53543849-40E87790-7849-4D24-959B-47E7054419FBQ54116026-C3568CEF-C759-47DF-A34A-B18D01A9C506Q54343782-AE6B7FA0-142B-4A4C-87AA-B06BD40D284FQ59809200-22FD84AF-AD72-4AE2-8E14-FA3B52F85070Q64106682-84346690-DB9D-4079-8D7F-AD40EF03A307Q64119616-95FC4415-48B5-4532-9723-7BF41D472343Q84095181-94698D22-EFB4-4C70-B85E-A5AB5BC88B90
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kengo Azushima
@ast
Kengo Azushima
@en
Kengo Azushima
@es
Kengo Azushima
@nl
Kengo Azushima
@sl
type
label
Kengo Azushima
@ast
Kengo Azushima
@en
Kengo Azushima
@es
Kengo Azushima
@nl
Kengo Azushima
@sl
prefLabel
Kengo Azushima
@ast
Kengo Azushima
@en
Kengo Azushima
@es
Kengo Azushima
@nl
Kengo Azushima
@sl
P106
P21
P31
P496
0000-0002-5136-0730
P569
2000-01-01T00:00:00Z